XGN
ExagenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case is that Exagen is showing measurable commercial execution: Q1 2026 revenue set a record, AVISE CTD volume and ASP both improved, gross margin held near 59%, and management reaffirmed full-year revenue guidance. If volume, ASP, and revenue-cycle management continue to offset operating expenses, losses could narrow and the market could give more credit to the turnaround.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +93.4.
What can break
Full-year 2026 revenue guidance of $70m-$73m is constructive but implies moderate growth rather than a breakout.
Momentum
95
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $12.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $12.14
Why
Momentum95 · Δ7d +93.4
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
52% active weight
Current posture
7d trendImproving
Δ7d
+93.4
Δ21d
+93.4
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.5 / Value 41.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$129.26M
Beta
1.91
Shares Out
22.66M
P/E (TTM) · Derived
-6.9
P/S (TTM)
2.12
P/FCF (TTM) · Derived
-10.51
Rev YoY
+37.9%
EPS YoY
-12.2%
Gross Margin
+59.9%
Op Margin
-20.1%
Net Debt
-$1.43M
Current Ratio
4.08
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology